PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1389 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-01-31

Study Completion Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this observational study is to give an overview of the use of PASCOE-Agil HOM-Injektopas in a 2-4 week treatment of rheumatic disorders.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Particulate vs. Non-Particulate Steroid for Sacroiliac Joint Injection

NCT06268704

Sacroiliac Joint Dysfunction Sacro-Iliac Spondylosis

RECRUITING PHASE4

Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis

NCT00997412

Myasthenia Gravis

UNKNOWN NA

Acthar in Treatment of Refractory Dermatomyositis and Polymyositis

NCT01906372

Dermatomyositis Polymyositis

COMPLETED PHASE2

An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis

NCT03896295

Generalized Myasthenia Gravis

TERMINATED PHASE2

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

NCT02473952

Myasthenia Gravis, Generalized

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this observational study is to give an overview of the use of PASCOE-Agil HOM-Injektopas in a 2-4 week treatment of rheumatic disorders of different aetiology and localisation, displaying a variety of symptoms.

Efficacy and tolerability of the drug will be assessed. Special regard will be taken to the administration management in relation to the Summary of Product Characteristics (SmPC).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatic Diseases Arthralgia Myalgias/Myopathy Lumbago

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observational group

Patients suffering from rheumatic disorders of different types and origins, especially those with arthralgia, myalgia, lumbago, or other diagnoses.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females
* At least 18 years old
* Rheumatic disease with accompanying symptoms, e.g. arthralgia, myalgia, lumbago etc.

Exclusion Criteria

* younger than 18 years
* no Rheumatic disease with accompanying symptoms, e.g. arthralgia, myalgia, lumbago etc.
* no treatment with PASCOE-Agil HOM-Injektopas

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No